Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug;3(8):624-37.
doi: 10.1016/S2213-8587(15)00129-1. Epub 2015 Jun 21.

Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331,288 participants

Collaborators

Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331,288 participants

NCD Risk Factor Collaboration (NCD-RisC). Lancet Diabetes Endocrinol. 2015 Aug.

Abstract

Background: Diabetes has been defined on the basis of different biomarkers, including fasting plasma glucose (FPG), 2-h plasma glucose in an oral glucose tolerance test (2hOGTT), and HbA1c. We assessed the effect of different diagnostic definitions on both the population prevalence of diabetes and the classification of previously undiagnosed individuals as having diabetes versus not having diabetes in a pooled analysis of data from population-based health examination surveys in different regions.

Methods: We used data from 96 population-based health examination surveys that had measured at least two of the biomarkers used for defining diabetes. Diabetes was defined using HbA1c (HbA1c ≥6·5% or history of diabetes diagnosis or using insulin or oral hypoglycaemic drugs) compared with either FPG only or FPG-or-2hOGTT definitions (FPG ≥7·0 mmol/L or 2hOGTT ≥11·1 mmol/L or history of diabetes or using insulin or oral hypoglycaemic drugs). We calculated diabetes prevalence, taking into account complex survey design and survey sample weights. We compared the prevalences of diabetes using different definitions graphically and by regression analyses. We calculated sensitivity and specificity of diabetes diagnosis based on HbA1c compared with diagnosis based on glucose among previously undiagnosed individuals (ie, excluding those with history of diabetes or using insulin or oral hypoglycaemic drugs). We calculated sensitivity and specificity in each survey, and then pooled results using a random-effects model. We assessed the sources of heterogeneity of sensitivity by meta-regressions for study characteristics selected a priori.

Findings: Population prevalence of diabetes based on FPG-or-2hOGTT was correlated with prevalence based on FPG alone (r=0·98), but was higher by 2-6 percentage points at different prevalence levels. Prevalence based on HbA1c was lower than prevalence based on FPG in 42·8% of age-sex-survey groups and higher in another 41·6%; in the other 15·6%, the two definitions provided similar prevalence estimates. The variation across studies in the relation between glucose-based and HbA1c-based prevalences was partly related to participants' age, followed by natural logarithm of per person gross domestic product, the year of survey, mean BMI, and whether the survey population was national, subnational, or from specific communities. Diabetes defined as HbA1c 6·5% or more had a pooled sensitivity of 52·8% (95% CI 51·3-54·3%) and a pooled specificity of 99·74% (99·71-99·78%) compared with FPG 7·0 mmol/L or more for diagnosing previously undiagnosed participants; sensitivity compared with diabetes defined based on FPG-or-2hOGTT was 30·5% (28·7-32·3%). None of the preselected study-level characteristics explained the heterogeneity in the sensitivity of HbA1c versus FPG.

Interpretation: Different biomarkers and definitions for diabetes can provide different estimates of population prevalence of diabetes, and differentially identify people without previous diagnosis as having diabetes. Using an HbA1c-based definition alone in health surveys will not identify a substantial proportion of previously undiagnosed people who would be considered as having diabetes using a glucose-based test.

Funding: Wellcome Trust, US National Institutes of Health.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study and data inclusion FPG=fasting plasma glucose. 2hOGTT=2-h oral glucose tolerance test. *The meta-analyses used inverse of variance as survey weights; sensitivity or specificity of either 0% or 100% would make the corresponding variance zero, and therefore the inverse of variance infinite.
Figure 2
Figure 2
Prevalence of diabetes defined by FPG-or-2hOGTT versus by FPG only FPG-or-2hOGTT definition was FPG 7·0 mmol/L or more, or 2hOGTT 11·1 mmol/L or more, or history of diabetes or using insulin or oral hypoglycaemic drugs. FPG only definition was FPG 7·0 mmol/L or more, or history of diabetes or using insulin or oral hypoglycaemic drugs. Each point shows one age–sex group in one survey. Table 1 shows the relation summarised as regression coefficients. FPG=fasting plasma glucose. 2hOGTT=2-h oral glucose tolerance test.
Figure 3
Figure 3
Prevalence of diabetes defined by HbA1c only versus prevalence defined by (A) FPG only, and (B) FPG-or-2hOGTT HbA1c definition was HbA1c 6·5% or more, or history of diabetes, or using insulin or oral hypoglycaemic drugs. FPG only definition was FPG 7·0 mmol/L or more, or history of diabetes or using insulin or oral hypoglycaemic drugs. FPG-or-2hOGTT definition was FPG 7·0 mmol/L or more, or 2hOGTT 11·1 mmol/L or more, or history of diabetes or using insulin or oral hypoglycaemic drugs. Each point shows one age–sex group in one survey. Table 2 shows the relations summarised as regression coefficients. FPG=fasting plasma glucose. 2hOGTT=2-h oral glucose tolerance test.

Comment in

References

    1. Danaei G, Finucane MM, Lu Y. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet. 2011;378:31–40. - PubMed
    1. Finucane MM, Stevens GA, Cowan MJ. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet. 2011;377:557–567. - PMC - PubMed
    1. Stevens GA, Singh GM, Lu Y. National, regional, and global trends in adult overweight and obesity prevalences. Popul Health Metr. 2012;10:22. - PMC - PubMed
    1. Kontis V, Mathers CD, Rehm J. Contribution of six risk factors to achieving the 25×25 non-communicable disease mortality reduction target: a modelling study. Lancet. 2014;384:427–437. - PubMed
    1. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol. 2014;2:634–647. - PMC - PubMed

Publication types